Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases

Patent metadata

Field	Value
Publication number	US-9486443-B2
Application number	US-201214361365-A
Country	US
Kind code	B2
Filing date	Nov 28, 2012
Priority date	Nov 30, 2011
Publication date	Nov 8, 2016
Grant date	Nov 8, 2016

Abstract

The present invention is a method for treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.

First claim

The invention claimed is:

1. A method for treating hypertriglyceridemia or a hypertriglyceridemia-associated disease in a patient, which comprises administering a therapeutically effective amount of a compound of Formula 1 or its pharmaceutically acceptable salt in combination with a therapeutically effective amount of amlodipine or its pharmaceutically acceptable salt to the patient in need thereof, wherein the combination is synergistic in treating the hypertriglyceridemia or hypertriglyceridemia-associated disease, and the weight ratio of the amount of the compound of Formula 1 or its pharmaceutically acceptable salt to the amount of amlodipine or its pharmaceutically acceptable salt is about 4:1:

2. The method according to claim 1 , wherein the compound of Formula 1 or its pharmaceutically acceptable salt in combination with amlodipine or its pharmaceutically acceptable salt are formulated into a dosage form for oral administration.

3. The method according to claim 2 , wherein the dosage form for oral administration comprises the compound of Formula 1 or its pharmaceutically acceptable salt in an amount suitable for administering in a dose ranging from 10 to 300 mg/day.

4. The method according to claim 2 , wherein the dosage form for oral administration comprises amlodipine or its pharmaceutically acceptable salt in an amount suitable for administering in a dose ranging from 5 to 320 mg/day.

5. The method according to claim 1 , wherein the hypertriglyceridemia-associated disease is combined hyperlipidemia, atherosclerosis, or pancreatitis.

Assignees

• Dae Woong Pharma

Inventors

• Lee Jong-Wook
• Lee Sang-Ho
• Lim Taek-Joo
• Koh Eun-Ji

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title